Cobra venom factor, Recombinant
Cat# HC4073-50UG
Size : 50ug
Brand : Hycult biotech
Contact local distributor :
Phone : +1 850 650 7790
Cobra Venom Factor, Recombinant
HC4073 is the recombinant form of Cobra venom factor (CVF) The complement system is the first line of defense against pathogens and important component of innate as well as adaptive immunity. CVF is the non-toxic complement activating protein in the venom from the cobra species Naja Kaouthia..
HC4073 is the recombinant form of Cobra venom factor (CVF). The complement system is the first line of defense against pathogens and important component of innate as well as adaptive immunity. CVF is the non-toxic complement activating protein in the venom from the cobra species Naja Kaouthia.
CVF is a structural and functional analog of complement C3. The protein functionally resembles C3b and exhibits a three-chain structure like C3c. CVF forms a C3/C5 convertase with factor B in the presence of factor D and Mg2+, thereby activating the alternative pathway of complement. Although analog in function, there are two differences between CVF,Bb convertases and natural C3b,Bb convertases.
First the stability is quite different. Whereas C3b,Bb is short-lived with a half-life of 1.5 min, CVF,Bb is rather stable with a half-life of 7h. Secondly, factor H disassembles C3b,Bb and serves as cofactor for proteolytic inactivation of C3b by factor I. The CVF convertase is completely resistant to factor H and I. Which makes it an excellent research tool. CVF is widely used reagent in order to deplete serum samples in order to study the role of complement in host defense, immune response and pathogenesis of disease.
Since the Naja species are on the list of endangered species, native CVF will increasingly difficult to obtain. The recombinant protein (rCVF)is synthesized in insect cells and is processed into a two-chain form of pro-CSF that structurally resembles C3 (Vogel et al). Pro-CVF can present in three forms and have all functional activity of mature, native CVF. The activity of pro-CVF and the resulting convertase is indistinguishable from CVF and the C3b,Bb convertase. rCVF can be exploited in vitro as well as in animals. This leads to decomplemented serum and high concentration of complement end products, like C3a, C5a and sTCC.
W: A reduced sample treatment and SDS-Page was used. The band size is ~150 kDa.
FS: Complement activation after incubation with CVF is tested by the lysis of sheep red blood cells.